Complementing these mechanisms, in KRAS-driven malignancies, suppression of the type I interferon (IFN) pathway emerges as a critical mechanism of tumor immune evasion, with pathway inactivation demonstrating strong correlation with concurrent activation of oncogenic signaling networks such as MYC (121). This evidence concerns the gene KRAS and neoplasm.